Hollis-Eden Rockets on Breast Cancer Drug Data

Shares of Hollis-Eden Pharmaceuticals rocketed over 50 percent to $2.51 early Friday after the company released promising early clinical data for its breast cancer drug candidate HE3235.
Market Watch